Evaluating Rimegepant for treating migraine attacks in China
A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
This study tests whether Rimegepant can help people in China feel better during migraine attacks and improve their overall satisfaction with treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 3 sites (Beijing, Beijing and 2 other locations) |
| Trial ID | NCT06439628 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of Rimegepant in treating acute migraine episodes. It will measure outcomes such as the severity of pain, the onset of pain relief, and overall satisfaction with treatment. Additionally, the study will evaluate long-term effects on treatment satisfaction and changes in migraine frequency over a year. Participants will be monitored for their response to the medication and any associated symptoms.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a primary diagnosis of migraine who have experienced migraine attacks for over a year.
Not a fit: Patients with severe cognitive impairments or those who cannot use digital tools for follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for patients suffering from acute migraine attacks.
How similar studies have performed: Other studies have shown promising results with Rimegepant for migraine treatment, suggesting a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Male or female participants aged ≥ 18 years-old 2. Primary diagnosis of migraine according to ICHD-3 3. Migraine attacks present for more than 1 year 4. Rimegepant is prescribed for the acute treatment of migraine by physician 5. Written informed consent must be obtained before participant is enrolled Exclusion Criteria: * Participants meeting any of the following criteria will not be included in the study: 1. Severe impairment of speech, vision, memory or cognition, or other factors that affect communication and ability to complete questionnaires and follow-up 2. Lack of necessary digital tools to complete questionnaires on a digital platform 3. History of hypersensitivity reaction to Rimegepant or to any of its components 4. Participants with severe hepatic impairment or end-stage renal disease 5. Any situation that the investigator believes may affect the patient's participation in the study
Where this trial is running
Beijing, Beijing and 2 other locations
- Chinese PLA General Hospital — Beijing, Beijing, China (Recruiting)
- Peking University People's Hospital — Beijing, Beijing, China (Recruiting)
- The Second Affiliated Hospital Zhejiang University School of Medicine — Hang Zhou, Zhenjiang, China (Recruiting)
Study contacts
- Study coordinator: Shengyuan Yu
- Email: yusy1963@126.com
- Phone: 8613501171068
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.